David Evans

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 4 CIPO patents and 3 EPO patents. Top assignees: Proximagen Limited, Cadlink Technology Corporation, Bio Products Laboratory Limited. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Evans. Retrieved from https://idiyas.com/inventor/david-evans-umlxvilo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 43.8

CIPO Patents = 4

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 4.3

ph-index = 5

Forward Citations = 50(Granted Patents)

Location History:

Ealing, GB (2008)
Bushey, GB (2010 - 2013)
London, GB (2009 - 2016)
Royston, GB (2017 - 2022)

Company Filing History:

Cadlink Technology Corporation

patents

1 out of 6

Bio Products Laboratory Limited

patents

4. 1 out of 8

Nhs Blood and Transplant

patents

Years Active: 2008-2022

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11512082 - Substituted imidazo[4,5-c]pyridine compounds and compositions thereof (2022-11-29),

2. 10968223 - Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors (2021-04-06),

3. 10766897 - Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors (2020-09-08),

4. 10590125 - Compounds (2020-03-17),

5. 10428066 - Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (2019-10-01),

6. 9951068 - Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (2018-04-24),

7. 9676769 - Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors (2017-06-13),

8. 9580415 - Compounds (2017-02-28),

9. 9428498 - Substituted imidazo[4,5-c]pyridine compounds and compositions thereof (2016-08-30),

10. 9227967 - Inhibitor compounds of semicarbazide-sensitive amine oxidases (2016-01-05),

11. 9150574 - Enzyme inhibitor compounds (2015-10-06),

12. 8435779 - Process for producing a virus-inactivated thrombin preparation (2013-05-07),

13. 7826099 - Variable-dot halftoning (2010-11-02),

14. 7816495 - Processes for the preparation of fibrinogen (2010-10-19),

15. 7586648 - Variable-dot halftoning (2009-09-08),

Title: The Innovative Contributions of David Evans

Introduction

David Evans is a notable inventor based in Royston, GB, recognized for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, Evans has made strides in developing compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents are the "Substituted imidazo[4,5-c]pyridine compounds and compositions thereof," which include a compound of formula (I) or a pharmaceutically acceptable salt, or N-oxide thereof, that serves as an inhibitor of SSAO activity. Another notable patent is for "Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors," which details a process for preparing a compound of formula (Ia) or a pharmaceutically acceptable salt, or N-oxide thereof, through specific chemical reactions.

Career Highlights

Throughout his career, David Evans has worked with several companies, including Proximagen Limited and Cadlink Technology Corporation. His work in these organizations has contributed to advancements in drug development and innovative pharmaceutical solutions.

Collaborations

Evans has collaborated with notable colleagues such as Iain Simpson and Edward Savory, enhancing the collaborative efforts in his research and development projects.

Conclusion

David Evans stands out as a prominent inventor whose work in pharmaceutical compounds has the potential to impact the industry significantly. His innovative spirit and dedication to research continue to drive advancements in the field.

Profile summary based on public USPTO records.